Personalised Surveillance in Ovarian Cancer: Does It Work?
Wednesday, January 27, 2027 at 4:30 PM to 5:00 PM · 30 min. (Europe/London)
Women & Children's Health Stage
Day 1 - Wednesday 27th January
CancerWomen & Children's Health
Information
- What personalised surveillance adds for women with pathogenic variants who are not yet ready for, or are waiting for, risk-reducing surgery.
- How longitudinal CA125 monitoring and the ROCA algorithm can help stratify risk and inform the clinical pathway, rather than simply providing a conventional “screening” test.
- The challenges around specificity and clinical decision-making, particularly when elevated CA125 levels may be associated with benign conditions such as endometriosis or polyps.
- The wider question of clinical utility. If risk-reducing surgery remains the definitive intervention, what value does surveillance provide to women and clinicians in the meantime?
- What we have learned from implementing the programme at UCLH, and what would need to happen for similar pathways to be adopted more widely across the NHS.
- Future directions, including whether genomic information, additional biomarkers, or other technologies could make personalised surveillance more predictive and clinically useful.
